Gimsing, P
,
Hjertner, Ø
Abildgaard, N
Andersen, N F
Dahl, T G
Gregersen, H
Klausen, T W
Mellqvist, U-H
Linder, O
Lindås, R
Tøffner Clausen, N
Lenhoff, S
Article History
Received: 16 October 2014
Revised: 21 March 2015
Accepted: 30 March 2015
First Online: 29 June 2015
Competing interests
: Janssen-Cilag supplied the study with free bortezomib and supported the expenses for conducting the study with a grant. Janssen-Cilag, together with Celgen and Mundipharma, are sponsors of The Nordic Myeloma Study Group. During the trial, the Nordic Myeloma Study Group has also received funding from the Nordic Cancer Union. P. Gimsing has received lecture honaria from Amgen. N. Abildgaard has received research grants Celgene and Janssen-Cilag. UH Mellqvist has received lecture honoraria from Celgene, Jansen, Mundipharma and Amgen. All remaining authors have declared no conflicts of interest.